Jason Kelly, CEO of Ginkgo Bioworks, argues that AI is the first technology revolution to fundamentally disrupt the core processes of biotechnology and scientific research, unlike previous waves like the internet.
Ginkgo Bioworks has strategically shifted its focus from AI-driven biological design to creating AI-powered robotic labs that automate the physical testing and experimentation phase, aiming to make it dramatically cheaper and faster.
This automation, which uses AI to translate natural language protocols into robotic actions, can increase lab equipment utilization from under 20% to over 70% and boost data output per R&D dollar by 10x.
Kelly envisions this platform shift democratizing science, enabling broad access to experimentation through cloud labs and accelerating the pace of discovery, which is critical amid rising geopolitical competition from China.
11 quotes
Concerns Raised
The traditional life sciences industry is slow to adopt new platforms and technologies.
The inherent complexity of biology remains a difficult 'science problem' to solve, even with better tools.
The rising pace of scientific discovery and drug development in China poses a significant competitive threat to the U.S.
The current R&D model in biopharma is highly inefficient, with most spending on labor and space rather than experiments.
Opportunities Identified
Using AI and robotics to automate the 'compile and debug' cycle of biological engineering, increasing throughput by an order of magnitude.
Fundamentally altering the economics of R&D by increasing equipment utilization and reducing the need for physical lab space.
Democratizing access to scientific experimentation through affordable, easy-to-use cloud lab services.
Leveraging government initiatives like Project Genesis to scale the adoption of autonomous labs and accelerate national scientific output.